Disruptive Tech Research
  • About
  • Media
  • Research
  • Subscribe
  • Log in
Select Page

[Video] Cue Biopharma Q&A Session With Dr. D.J. Verret

by Lou Basenese | Feb 21, 2022 | CUE

In this 1.5 hour webinar, Dr. D.J. Verret shares his unique clinical perspective on Cue Biopharma’s (CUE) approach and latest data

[CUE] “That Data Is Amazing!” So Why Is The Stock Down?

[CUE] “That Data Is Amazing!” So Why Is The Stock Down?

by Lou Basenese | Jan 27, 2022 | CUE

Here’s a full rundown on the important takeaways from CUE’s conference call and my thoughts on the recent trading activity…

[Video] What To Expect From CUE This Afternoon

[Video] What To Expect From CUE This Afternoon

by Lou Basenese | Jan 26, 2022 | CUE

Like expectant parents, everyone’s wondering what will be revealed on today’s update call. Here are my reasonable expectations…

CUE Q1 2019 Key Takeaways: Despite IR Misstep, On Track For Data-Rich, “Transformational” Year

CUE Q1 2019 Key Takeaways: Despite IR Misstep, On Track For Data-Rich, “Transformational” Year

by Lou Basenese | May 23, 2019 | CUE

Five key takeaways from Cue Biopharma’s Q1 2019 report, including the list of catalysts management believes will result in 2019 being a “transformational” year…

CUE: Major Milestone Met On Path to Immunotherapy Market Disruption

CUE: Major Milestone Met On Path to Immunotherapy Market Disruption

by Lou Basenese | May 16, 2019 | CUE

Here are three reasons why today’s FDA approval to enter the clinic with CUE-101 for HPV-associated cancers is significant, including two not so obvious reasons. Plus, a list of catalysts for 2019…

« Older Entries

Your account

Sign in

Research Links

  • Real-Time Blog
  • Active Recs
  • Archive

Recent Posts

  • Q2 2022 Portfolio Review & Outlook
  • ATOM: Lands Another “Major” Foundry Customer, Plus 10 Takeaways From Q1 Report
  • [IMNM] Biotech Absurdity
  • [Video] Cue Biopharma Q&A Session With Dr. D.J. Verret
  • [Video] ATOM: 5 Key Takeaways From The Q4 2021 Report
  • RESN: Time To Lock In Our 5G Gains
  • [CUE] “That Data Is Amazing!” So Why Is The Stock Down?